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nhibition by Aspirin, Clopidogrel, or Their Combination
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elvin L. Moeschberger, PHD,† David J. Frid, MD, FACC,* Raymond D. Magorien, MD, FACC,*
aul F. Bray, MD,‡ Philip F. Binkley, MD, MPH, FACC,* Pascal J. Goldschmidt-Clermont, MD, FACC§
olumbus, Ohio; Houston, Texas; and Durham, North Carolina
OBJECTIVES We studied the modifier effect of platelet antigen polymorphism (PlA2) on platelet inhibition
by acetylsalicylic acid (ASA, i.e., aspirin), clopidogrel, or their combination in patients with
coronary heart disease.
BACKGROUND Clopidogrel, when administered with ASA, was shown to significantly improve the outcome
of patients with acute coronary syndromes compared with patients receiving only ASA. We
have shown previously that the effect of ASA on platelets is modified by the glycoprotein IIIa
single nucleotide polymorphism PlA2. Hence, an important pharmacogenetic question
remains whether the antiplatelet effect of clopidogrel is uniform for all patients or, like
acetylsalicylic acid, more selective.
METHODS Thirty PlA1/A1 and 30 PlA1/A2 patients were assigned randomly to ASA 325 mg/day,
clopidogrel 75 mg/day, or both. After 10 days, platelet function was studied.
RESULTS Clopidogrel provided stronger platelet inhibition than ASA with adenosine diphosphate as
the agonist, and combination therapy resulted in greater inhibition than either inhibitor used
alone (p 0.0001). The use of ASA resulted in greater inhibition compared with clopidogrel
with epinephrine (p  0.0001) and collagen as agonists (p  0.0001). With collagen as the
agonist, platelets from PlA1/A2 donors were markedly and significantly less inhibited by ASA
(p 0.005). In contrast, with clopidogrel, no significant difference could be detected between
inhibition of PlA1/A1 and PlA1/A2 platelets.
CONCLUSIONS The combination of ASA and clopidogrel appears superior to either agent alone in inhibiting
platelet function. PlA2 functions as an important modifier for platelet responsiveness to ASA
but not to clopidogrel. These findings could have significant impact on the future design of
pharmacogenetic antithrombotic strategies for patients with coronary heart disease. (J Am
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.09.034Coll Cardiol 2006;47:541–6) © 2006 by the American College of Cardiology Foundation
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pt is well established that platelets and inflammation play a
entral role in coronary atherosclerotic heart disease and its
onsequences (i.e., unstable angina, myocardial infarction,
nd sudden cardiac death) (1,2), with numerous large
linical trials demonstrating significant benefit of platelet
nhibition with various agents (3–7). Clopidogrel is an
nhibitor of adenosine diphosphate (ADP)-induced platelet
ggregation by reducing ADP binding to its receptor (8,9).
lopidogrel’s clinical efficacy was demonstrated in the Clopi-
ogrel vs. Aspirin in Patients at Risk of Ischemic Events
CAPRIE) trial, in which its long-term administration to
atients with atherosclerosis was more effective than aspirin
n reducing atherothrombotic complications (10). Animal
odels of thrombosis suggest that combination therapy
ith aspirin is an even more effective antithrombotic strat-
gy (11–13) and, in a large randomized trial in patients with
cute coronary syndromes, the combination of acetylsalicylic
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005, accepted September 19, 2005.cid (ASA, i.e., aspirin) and clopidogrel was shown superior
o ASA alone (14). The risk of major bleeding was increased
ith combination therapy relative to ASA alone and,
herefore, it becomes important to identify means of select-
ng patients whose need for clopidogrel, in addition to ASA,
s greatest to achieve optimized platelet inhibition.
We have hypothesized that the efficiency and safety of
ntithrombotic strategies might be impacted by specific
ene variants implicated in coronary thrombosis under
arious clinical circumstances (15,16). This pilot trial was
esigned to assess the relative efficacy of aspirin, clopidogrel,
r their combination in inhibiting ex vivo platelet function
n a cohort of patients with established coronary heart
isease (CHD). We demonstrate that platelet function is
arkedly dependent upon the type of agonist used, agonist
oncentration, antiplatelet strategy, and the platelet antigen
olymorphism (PlA) genotype. The latter finding could have
mportant pharmacogenetic consequences for the design of
ntithrombotic strategies for patients with CHD.
ETHODS
tudy subjects. To study the effects of the PlA phenotype
n in vivo antiplatelet therapy, we genotyped a cohort of
atients with established and stable coronary artery disease,
erified by cardiac catheterization, who require long-term
a
s
c
H
p
g
g
s
e
t
(
d
A
c
w
b
c
P
m
c
f
f
c
s

(
c
H
P
t
p
p
a
S
a
p
c
a
4
P

1
t
p
fi
E
a
p
F
w
n
P
c
J
a
l
F
S
c
a
‡
542 Cooke et al. JACC Vol. 47, No. 3, 2006
PlA and Responsiveness to Aspirin and Clopidogrel February 7, 2006:541–6ntiplatelet therapy for secondary prevention. All study
ubjects provided written informed consent, and the proto-
ol was approved by the Institutional Review Board for
uman Subjects of the Ohio State University. We com-
ared two groups of subjects that were matched for age,
ender, race, medical history, and blood pressure. The first
roup consisted of 30 PlA1/A1 homozygotes, and 30 PlA1/A2
ubjects comprised the second group. Ten subjects from
ach group were assigned randomly to receive one of three
reatment regimens for 10 days. The regimens were ASA
325 mg, daily) alone (10 PlA1/A1 and 10 PlA1/A2), clopi-
ogrel (75 mg, daily) alone (10 PlA1/A1 and 10 PlA1/A2), or
SA (325 mg, daily) and clopidogrel (75 mg daily) in
ombination (10 PlA1/A1 and 10 PlA1/A2). Platelet assays
ere performed after 10 days of therapy (enough time for
oth drugs to reach steady state). All patient data were
oded to maintain a blinded evaluation.
latelet preparation. Phlebotomy was performed in the
orning within 4 h of the patients ingesting study medi-
ation, under fasting conditions, and without caffeine intake
or at least 12 h. Platelet-rich plasma (PRP) was obtained
rom citrated blood as previously reported (17). Five con-
entrations of three conventional agonists were used in
igure 1. Aggregation (mean percent  SEM) with adenosine diphospha
ignificant differences under different conditions of blockade were noted.
oncentrations revealed significant differences (p  0.05) between treatm
Abbreviations and Acronyms
ADP  adenosine diphosphate
ANOVA  analysis of variance
ASA  acetylsalicylic acid
CHD  coronary heart disease
GP  glycoprotein
PlA  platelet antigen polymorphism
PRP  platelet-rich plasmacetylsalicylic acid (ASA) and with clopidogrel. †Applies for differences between
Applies for differences between treatment with ASA and with ASA plus clopeparate assays, including epinephrine (0, 0.5, 1, 2, 5, and 10
mol/l; Sigma Chemical Co., St. Louis, Missouri), ADP
0.5, 1, 2, 5, and 10 mol/l; Sigma Chemical Co.), and
ollagen (type 1; 0, 0.5, 1, 2, 5, and 10 g/ml; Chrono-log,
avertown, Pennsylvania).
latelet aggregation. A standardized platelet concentra-
ion of 300,000 platelets/l for a 250-l reaction was
repared by dilution of PRP with autologous plasma de-
leted of platelets after a platelet count was determined with
Z1 Coulter counter (Coulter Corp., Miami, Florida).
amples were incubated at 37° for 30 min before the
ggregation assay using the method of Born (18). Separate
latelet aggregation assays were performed with various
oncentrations of agonists under constant shear (1,000 rpm)
nd temperature (37°) for 15 min in a Chrono-log 470-VS
-channel aggregometer (Chrono-log).
latelet glycoprotein (GP) IIb/IIIa activation and
-granule release. Platelets from PRP were diluted to
,000 platelets/l with Tyrode’s buffer in polypropylene
ubes. To assess GP IIb/IIIa receptor activation, resting
latelets were supplemented with fluorescein isothiocyanate-
brinogen (4.7 g/ml final concentration, Molecular Probes,
ugene, Oregon) before agonist stimulation. Ten minutes
fter exposure to agonist, the reaction was stopped, and the
latelets were fixed in formaldehyde (1.5% final concentration,
isher Scientific, Pittsburgh, Pennsylvania). Fixed platelets
ere then incubated with phycoerythrin-conjugated monoclo-
al antibody CD62P (0.09 g/ml final concentration, BD
harMingen, San Diego, California) and analyzed by two-
olor flow cytometry (FACS Calibur, Becton Dickinson, San
ose, California). Ten thousand gated events were collected
nd analyzed using Cellquest software. All data were stored in
istmode fashion for archiving.
, collagen (B), or epinephrine (C) in study subjects by treatment strategy.
tiple comparisons (six included in adjustment per plot) at each agonist’s
strategies as indicated. *Applies for differences between treatment withte (A)
Mul
enttreatment with clopidogrel and with ASA plus clopidogrel in combination.
idogrel in combination.
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February 7, 2006:541–6 PlA and Responsiveness to Aspirin and Clopidogrelata analysis. All patient data were coded to maintain a
linded evaluation. For baseline clinical data, a chi-square
nalysis was used for categorical data and a Student t test for
ontinuous variables. For platelet aggregation and GP
Ib/IIIa activation data, a three-factor (PlA genotype, treat-
ent strategy, and agonist concentration) analysis of vari-
nce (ANOVA) with one repeated factor (agonist concen-
ration) was performed separately for each agonist.
odeling was performed by PROC Mixed procedure in
AS Version 8.1 (SAS Institute, Cary, North Carolina)
19,20). Multiple comparisons were made (if significant
ifferences were found) with least square means analysis
ith the Bonferroni adjustment (21). Data were trans-
ormed if normality and equal variances of the residuals were
ot met. In all ANOVA models on the raw data, neither the
qual variances nor the normality assumptions on the error
erms were met. The normality and equal variances assump-
ions were examined on the residuals from the ANOVA
ith the Shapiro-Wilkes test and the plots, respectively.
herefore, the data were transformed using a square-root
ransformation, and all statistical analyses are based on the
ransformed data. The assumptions were again checked
fter the square-root transformation, and they appeared to
e met.
ESULTS
lopidogrel provided significantly greater inhibition of
latelet aggregation induced with ADP, and even more
nhibition was observed when clopidogrel was added to
SA as compared with treatment with ASA only (Fig. 1A; p
0.0001). With collagen, significant differences were found
etween treatments (Fig. 1B; p  0.0001), with ASA plus
lopidogrel and also ASA-only treatments, providing signifi-
antly greater inhibition when compared with clopidogrel.
ith epinephrine, ASA significantly inhibited aggregation
hen compared with clopidogrel (Fig. 1C; p 0.0001), with
o added benefit of clopidogrel in combination therapy with
SA. Similar to aggregation, fluorescein isothiocyanate-
brinogen binding was significantly reduced by clopidogrel
nd the clopidogrel-plus-ASA combination therapy com-
ared with ASA only with ADP stimulation (Fig. 2; p 
.01). However, this treatment effect in ADP-stimulated
latelets was not observed between treatment strategies for
-granule release as assessed by CD62P binding (p 0.89).
We then investigated the effect of the PlA polymorphism.
he PlA genotype effect on platelet inhibition was markedly
tronger when collagen was used as the agonist compared with
pinephrine and less strong with ADP. An interaction was
oted between ADP concentration and genotype (Fig. 3A;
 0.005) in terms of aggregation, but this genotype effect
as not statistically significant in GP IIb/IIIa activation
p  0.21) or in -granule release (p  0.31). With
ollagen, PlA1/A1 platelets were significantly more inhibited
y ASA than PlA1/A2 platelets in terms of aggregation (Fig. pB; p  0.005) and GP IIb/IIIa activation (Fig. 4; p 
.0001) as assessed by fibrinogen binding. The difference
etween PlA1/A1 and PlA1/A2 platelets was significant,
hether with ASA alone or combination therapy (Fig. 3B).
o statistically significant interaction was noted between
pinephrine concentration and genotype with the dosage(s)
f antiplatelet drug(s) used.
Finally, alpha-granule release in collagen-stimulated plate-
ets was dependent on PlA genotype, treatment strategy, and
gonist concentration (Fig. 5; p  0.005). PlA1/A2 platelets
ad significantly higher alpha-granule release regardless
f treatment strategy at higher concentrations of collagen,
hereas in PlA1/A1 platelets, the addition of clopidogrel
o ASA therapy yielded further decreases in CD62P
xpression.
ISCUSSION
n this report, we demonstrate that the PlA2 polymorphism
ignificantly modifies the inhibition of platelet function
rought about by ASA and clopidogrel and is dependent on
he agonist used. When collagen stimulates aggregation,
lopidogrel behaves as a weak inhibitor relative to ASA.
owever, when added to ASA, the combination of the two
rugs is marginally more efficient than ASA alone, an
ncremental effect that is not observed with epinephrine as
he agonist. These interactions between agonists and inhib-
tors are highly instructive and, in the case of collagen,
ssociated with strong concurrent interaction with the
latelet SNP (T1565C), PlA.
We demonstrate that with collagen stimulation, PlA1/A2
igure 2. Fluorescein isothiocyanate (FITC)-fibrinogen binding (mean
uorescence units  SEM) with adenosine diphosphate (ADP) in study
ubjects by treatment strategy. Significant differences under different
onditions of blockade were noted (p  0.01). Multiple comparisons (six
ncluded in adjustment per plot) at each agonist’s concentrations revealed
ignificant differences (p 0.05) between treatment strategies as indicated.
Applies for differences between treatment with acetylsalicylic acid (ASA)
nd with clopidogrel. ‡Applies for differences treatment with acetylsalicylic
cid (ASA) and with ASA plus clopidogrel in combination.latelets are significantly less well inhibited by ASA than
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lopidogrel is added to ASA, the inhibition of PlA1/A2
latelets is still less than that of their PlA1/A1 counterpart;
lthough PlA1/A1 platelets benefit incrementally by the
ddition of clopidogrel to ASA, PlA1/A2 platelets do not.
onsidering that most patients display the PlA1/A1 geno-
ype, this mild effect of clopidogrel inhibition also could
ccount for some of the relative clinical superiority of the
SA-plus-clopidogrel combination compared with the use
f only ASA. In a study of ADP-stimulated platelet reactivity
n patients with stents, Angiollilo et al. (22) reported that a
00-mg clopidogrel loading dose had less of an effect in
lA1/A2 subjects. One main difference between this study
nd our report is that we treated subjects for 10 days, during
hich time steady state clearly is achieved. It would appear
hat the 300-mg loading dose is not enough to induce rapid
nhibition for patients who need it (22). This finding is
igure 3. Aggregation (mean percent SEM) with adenosine diphosphate
s a significant interaction between agonist concentration and indicated PlA
 0.005). Multiple comparisons (six included in adjustment per plot) at e
lA1/A1 and PlA1/A2 as indicated. *Applies for differences between PlA1/A1onsistent with our previous statement that PlA1/A2 individ- pals treated with 250 mg of ticlopidine had five times the
ate of stent thrombosis as that observed with 500 mg of
iclopidine (16).
Since our initial report on the differential sensitivity of
latelets to aspirin as a function of the PlA polymorphism
15), it appears that there have been discordant results either
ubstantiating (23) or conflicting our results (24–26). In
heir initial study, Undas et al. (24) found that PlA1/A1
ndividuals had significantly greater platelet inhibition with
SA than PlA1/A2 individuals. They reported that carriers
f the PlA2 polymorphism appeared to be more resistant to
SA than noncarriers, as measured by bleeding times (25).
n this setting, collagen is likely to function as a key agonist
or platelets that escape disrupted vessels in the skin, and we
ave shown in this study that inhibition of collagen-induced
ggregation with ASA is more efficient for PlA1/A1 patients
han for PlA1/A2 patients. However, we also show the PlA
P) (A) or collagen (B) dichotomized according to the PlA genotype. There
type for aggregation induced with ADP (A, p  0.005) and collagen (B,
gonist’s concentrations revealed significant differences (p  0.05) between
PlA1/A2.(AD
geno
ach aolymorphism has modifier effects on platelet inhibition by
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February 7, 2006:541–6 PlA and Responsiveness to Aspirin and ClopidogrelSA that can vary with the agonist (epinephrine vs.
ollagen). Macchi et al. (26) further substantiate this con-
ept in a study that demonstrated ASA-resistant patients
ere more likely to be of the PlA1/A1 genotype. In this study,
esistance to ASA was determined with the platelet function
nalyzer (PFA-100), utilizing a collagen/epinephrine-coated
artridge. It is possible that in stimulating platelets in this
ystem, epinephrine may yield the predominate effect.
hese results may help to understand and reconcile the
ivergent results reported.
In their interesting study of post-MI patients, Moshfegh
t al. (27) reported greater inhibition with clopidogrel and
ombination of ASA plus clopidogrel compared with ASA
lone in ADP-stimulated aggregation in vitro. We were
ble to confirm their findings with our study of patients with
igure 4. Collagen-stimulated PlA1/A1 platelets were significantly more in
ssessed by fluorescein isothiocyanate-fibrinogen binding (mean fluorescen
t each concentrations of collagen revealed significant differences (p  0.0
etween PlA1/A1 and PlA1/A2.igure 5. In collagen-stimulated platelets, -granule release (as measured by C
trategy, and agonist concentration (mean fluorescence units  SEM; p  0.00table CHD. Thus, it is possible that the clinical benefit of
lopidogrel, when added to ASA, is mediated by the
ncremental inhibition of ADP-stimulated platelet re-
ponse. In the CAPRIE trial, the use of clopidogrel alone
as shown superior to ASA, although the difference be-
ween the two inhibitors was marginal (10). In the CURE
rial, the first primary outcome difference between ASA/
lacebo versus ASA/clopidogrel combination (20% relative risk
eduction) was two to three times greater than the outcome
ifference between ASA and clopidogrel (CAPRIE: 9%
elative risk reduction) (10,14). Synergy between receptor
athways is plausibly responsible for the additive effect of
SA on platelet inhibition (Tx-receptor pathway) in the
resence of ADP as an agonist and clopidogrel as an
nhibitor of the purinergic receptor pathway.
ed by acetylsalicylic acid (aspirin) than PlA1/A2 platelets (p  0.0001) as
its  SEM). Multiple comparisons (six included in adjustment per plot)
tween PlA1/A1 and PlA1/A2 platelets as indicated. *Applies for differences
Ahibit
ce unD62P; P-selectin expression) was dependent on Pl genotype, treatment
5).
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PlA and Responsiveness to Aspirin and Clopidogrel February 7, 2006:541–6Our study provides the rationale for additional large
harmacogenetic trials, trials that represent a true opportu-
ity to learn how to target therapeutic strategies to patients
hose benefit would be greatest, thereby providing an
pportunity to limit side effects and cost for large popula-
ions of patients with CHD.
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